SMT201600013B - Procedimento per la preparazione di acidi, esteri e ammidi [(3-idrossipiridin-2-carbonil) ammino]alcanoici - Google Patents
Procedimento per la preparazione di acidi, esteri e ammidi [(3-idrossipiridin-2-carbonil) ammino]alcanoiciInfo
- Publication number
- SMT201600013B SMT201600013B SM201600013T SM201600013T SMT201600013B SM T201600013 B SMT201600013 B SM T201600013B SM 201600013 T SM201600013 T SM 201600013T SM 201600013 T SM201600013 T SM 201600013T SM T201600013 B SMT201600013 B SM T201600013B
- Authority
- SM
- San Marino
- Prior art keywords
- hydroxypylidin
- ammids
- alcanoanic
- carbonyl
- esters
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/803—Processes of preparation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/824—Palladium
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161493536P | 2011-06-06 | 2011-06-06 | |
PCT/US2012/040833 WO2012170377A1 (en) | 2011-06-06 | 2012-06-05 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides |
Publications (1)
Publication Number | Publication Date |
---|---|
SMT201600013B true SMT201600013B (it) | 2016-02-25 |
Family
ID=47262177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SM201600013T SMT201600013B (it) | 2011-06-06 | 2016-01-15 | Procedimento per la preparazione di acidi, esteri e ammidi [(3-idrossipiridin-2-carbonil) ammino]alcanoici |
Country Status (24)
Country | Link |
---|---|
US (6) | US9145366B2 (it) |
EP (5) | EP4026829A1 (it) |
JP (6) | JP6290781B2 (it) |
KR (5) | KR102000485B1 (it) |
CN (1) | CN106518759B (it) |
AU (4) | AU2012268426B2 (it) |
CA (2) | CA3135440A1 (it) |
CY (4) | CY1117177T1 (it) |
DK (4) | DK3000808T3 (it) |
ES (4) | ES2771232T3 (it) |
HK (3) | HK1196616A1 (it) |
HR (4) | HRP20211916T1 (it) |
HU (4) | HUE057571T2 (it) |
IL (1) | IL229775A (it) |
LT (3) | LT3683209T (it) |
MX (2) | MX347709B (it) |
NO (1) | NO2686520T3 (it) |
PL (4) | PL3290404T3 (it) |
PT (4) | PT3290404T (it) |
RS (3) | RS59902B1 (it) |
RU (2) | RU2602083C2 (it) |
SI (4) | SI2718265T1 (it) |
SM (1) | SMT201600013B (it) |
WO (1) | WO2012170377A1 (it) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2922078T3 (es) | 2006-06-26 | 2022-09-07 | Akebia Therapeutics Inc | Inhibidores de prolil hidroxilasa y métodos de uso |
NO2686520T3 (it) | 2011-06-06 | 2018-03-17 | ||
RU2019134558A (ru) * | 2013-06-13 | 2020-02-20 | Экебиа Терапьютикс, Инк. | Композиции и способы лечения анемии |
KR102381295B1 (ko) | 2013-11-15 | 2022-03-31 | 아케비아 테라퓨틱스 인코포레이티드 | {[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노}아세트산의 고체형, 이의 조성물 및 용도 |
AU2015311333B2 (en) | 2014-09-02 | 2017-11-16 | Sunshine Lake Pharma Co., Ltd. | Quinolinone compound and use thereof |
TW201632504A (zh) | 2015-01-23 | 2016-09-16 | 阿克比治療有限公司 | 2-(5-(3-氟苯基)-3-羥吡啶醯胺基)乙酸之固體形式、其組合物及其用途 |
WO2016153996A1 (en) * | 2015-03-20 | 2016-09-29 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
CN106146395B (zh) * | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3-羟基吡啶化合物、其制备方法及其制药用途 |
BR112017021097B1 (pt) | 2015-04-01 | 2024-01-02 | Akebia Therapeutics, Inc | Formulação de dosagem oral e seu uso |
JP2020500925A (ja) * | 2016-12-13 | 2020-01-16 | クリスタル ファーマシューティカル(スーチョウ)カンパニー,リミテッド | {[5−(3−クロロフェニル)−3−ヒドロキシピリジン−2−カルボニル]アミノ}酢酸の新規結晶形及びその製造方法 |
AU2017406103B2 (en) * | 2017-03-29 | 2023-12-14 | Emerald Health Pharmaceuticals, Inc. | Cannabidiol derivatives as inhibitors of the HIF prolyl hydroxylases activity |
WO2019028150A1 (en) | 2017-08-01 | 2019-02-07 | Akebia Therapeutics, Inc. | COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES |
KR20210006967A (ko) * | 2018-05-09 | 2021-01-19 | 아케비아 테라퓨틱스 인코포레이티드 | 2-[[5-(3-클로로페닐)-3-하이드록시피리딘-2-카르보닐]아미노]아세트산을 제조하는 방법 |
WO2020075199A1 (en) | 2018-10-12 | 2020-04-16 | Mylan Laboratories Limited | Polymorphic forms of vadadustat |
EP3887356B1 (en) | 2018-11-28 | 2023-08-02 | Sandoz AG | Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor |
WO2020217733A1 (ja) * | 2019-04-26 | 2020-10-29 | 株式会社カネカ | Vadadustat中間体の製造方法 |
US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
CN111087343B (zh) * | 2019-11-29 | 2022-02-18 | 万华化学集团股份有限公司 | 一种羟基吡啶配体及其制备方法和催化应用 |
WO2021117767A1 (ja) * | 2019-12-10 | 2021-06-17 | 田辺三菱製薬株式会社 | 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法 |
WO2021149724A1 (ja) | 2020-01-24 | 2021-07-29 | Apsジャパン株式会社 | 光触媒ユニット及び該光触媒ユニットを備えたマスク |
US20230286918A1 (en) * | 2020-07-02 | 2023-09-14 | Akebia Therapeutics, Inc. | Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat |
GB202011431D0 (en) * | 2020-07-23 | 2020-09-09 | Johnson Matthey Plc | Polymorphs of vadadustat and methods for preparing the polymorphs |
WO2023111990A1 (en) | 2021-12-17 | 2023-06-22 | Akebia Therapeutics, Inc. | Selective phd1 inhibitor compounds, compositions, and methods of use |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3655679A (en) * | 1969-06-25 | 1972-04-11 | Merck & Co Inc | Certain aryl pyridine carboxylic acid derivatives |
US3703582A (en) * | 1970-04-20 | 1972-11-21 | Merck & Co Inc | Aryl pyridine carboxylic acids in the treatment of inflammation |
US3894920A (en) | 1971-12-21 | 1975-07-15 | Sagami Chem Res | Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives |
US4016287A (en) | 1972-07-17 | 1977-04-05 | Boehringer Ingelheim Gmbh | Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof |
TW219933B (it) | 1990-02-26 | 1994-02-01 | Lilly Co Eli | |
US5405613A (en) | 1991-12-11 | 1995-04-11 | Creative Nutrition Canada Corp. | Vitamin/mineral composition |
TW352384B (en) | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
DE4219158A1 (de) | 1992-06-11 | 1993-12-16 | Thomae Gmbh Dr K | Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
ES2101420T3 (es) * | 1993-11-02 | 1997-07-01 | Hoechst Ag | Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. |
ATE149486T1 (de) | 1993-11-02 | 1997-03-15 | Hoechst Ag | Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel |
TW406076B (en) | 1993-12-30 | 2000-09-21 | Hoechst Ag | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
DE4410423A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE4410480A1 (de) | 1994-03-25 | 1995-09-28 | Hoechst Ag | Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US5789426A (en) | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
JPH09221476A (ja) | 1995-12-15 | 1997-08-26 | Otsuka Pharmaceut Co Ltd | 医薬組成物 |
KR20000065090A (ko) | 1996-04-30 | 2000-11-06 | 훽스트 악티엔게젤샤프트 | 3-알콕시피리딘-2-카복실산아미드에스테르,이의제조방법및약제로서의이의용도 |
DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
DE19650215A1 (de) | 1996-12-04 | 1998-06-10 | Hoechst Ag | 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
EP1024134A4 (en) | 1997-10-09 | 2003-05-14 | Ono Pharmaceutical Co | DERIVATIVES OF AMINOBUTANIC ACID |
DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
ES2224620T3 (es) | 1998-03-23 | 2005-03-01 | Aventis Pharmaceuticals Inc. | Derivados de piperidinilo y n-aminopiperidinilo. |
US6159379A (en) | 1999-05-04 | 2000-12-12 | Baker Hughes Incorporated | Organic ammonium salts for the removal of water soluble organics in produced water |
JP2001048786A (ja) | 1999-08-05 | 2001-02-20 | Yamanouchi Pharmaceut Co Ltd | 三環式ヘテロアリール誘導体 |
US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
US6855510B2 (en) | 2001-03-20 | 2005-02-15 | Dana Farber Cancer Institute, Inc. | Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
US6849718B2 (en) | 2001-03-20 | 2005-02-01 | Dana Farber Cancer Institute, Inc. | Muteins of hypoxia inducible factor alpha and methods of use thereof |
US20040146964A1 (en) | 2001-03-21 | 2004-07-29 | Maxwell Patrick Henry | Assays, methods and means |
SE0101327D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | New crystalline forms |
US6566088B1 (en) | 2001-10-04 | 2003-05-20 | Board Of Regents, The University Of Texas System | Prolyl-4-hydroxylases |
GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
WO2003049686A2 (en) | 2001-12-06 | 2003-06-19 | Fibrogen, Inc. | Stabilization of hypoxia inducible factor (hif) alpha |
AU2003234624B8 (en) | 2002-05-17 | 2009-03-12 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
JP2005537323A (ja) * | 2002-08-29 | 2005-12-08 | メルク エンド カムパニー インコーポレーテッド | N−ビアリールメチルアミノシクロアルカンカルボキサミド誘導体 |
EP1554394B1 (en) | 2002-10-16 | 2009-12-16 | Isis Innovation Limited | Screening methods using a structural model of FIH |
CA2506799A1 (en) | 2002-11-21 | 2004-06-10 | Eli Lilly And Company | Mixed lineage kinase modulators |
US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
US20060251638A1 (en) | 2003-06-06 | 2006-11-09 | Volkmar Guenzler-Pukall | Cytoprotection through the use of hif hydroxylase inhibitors |
KR100932169B1 (ko) | 2003-06-06 | 2009-12-16 | 피브로겐, 인크. | 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용 |
GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
JPWO2005108370A1 (ja) | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
ATE443775T1 (de) | 2004-05-28 | 2009-10-15 | Fibrogen Inc | Hif-prolylhydroxylase-aktivitätstest |
EP1771418A2 (en) | 2004-05-31 | 2007-04-11 | Tanabe Seiyaku Co., Ltd. | Large conductance calcium-activated k channel opener |
BRPI0511834A (pt) | 2004-07-14 | 2008-01-08 | Ptc Therapeutics Inc | métodos por tratar hepatite c |
TW200616969A (en) | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
US20080213404A1 (en) | 2005-02-04 | 2008-09-04 | Johnson Randall S | Hif Modulating Compounds and Methods of Use Thereof |
DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
CN101394843A (zh) | 2005-06-06 | 2009-03-25 | 菲布罗根公司 | 使用HIFα稳定剂的改进的贫血治疗 |
US8530404B2 (en) | 2005-06-15 | 2013-09-10 | Fibrogen, Inc. | Compounds and methods for treatment of cancer |
WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
US20090176726A1 (en) | 2005-10-11 | 2009-07-09 | Fisher David E | Methods for treating mitf-related disorders |
EP1960363B1 (en) | 2005-12-09 | 2014-01-22 | Amgen, Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof |
BRPI0706377A2 (pt) | 2006-01-09 | 2011-03-22 | Btg Int Ltd | moduladores de fator -1 induzìvel por hipoxia e usos relacionados |
WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
US20070208053A1 (en) | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
JP4801451B2 (ja) | 2006-01-19 | 2011-10-26 | 株式会社日立ハイテクノロジーズ | 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法 |
ITMI20060179A1 (it) | 2006-02-02 | 2007-08-03 | Abiogen Pharma Spa | Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse |
WO2007101204A1 (en) | 2006-02-27 | 2007-09-07 | Alcon Research, Ltd. | Method of treating glaucoma |
TW200808793A (en) | 2006-03-07 | 2008-02-16 | Smithkline Beecham Corp | Prolyl hydroxylase inhibitors |
US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
JP2009537558A (ja) | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
JO2934B1 (en) | 2006-06-23 | 2015-09-15 | سميث كلاين بيتشام كوربوريشن | Prolyl hydroxylase inhibitors |
ES2922078T3 (es) | 2006-06-26 | 2022-09-07 | Akebia Therapeutics Inc | Inhibidores de prolil hidroxilasa y métodos de uso |
TW200845994A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
CL2008000066A1 (es) | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
EP2155680B1 (en) | 2007-04-18 | 2013-12-04 | Amgen, Inc | Indanone derivatives that inhibit prolyl hydroxylase |
WO2008130527A1 (en) | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
ES2389063T3 (es) | 2007-05-04 | 2012-10-22 | Amgen, Inc | Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa |
WO2008144266A1 (en) | 2007-05-16 | 2008-11-27 | Merck & Co., Inc. | Spiroindalones |
CN101765596B (zh) | 2007-05-18 | 2015-04-29 | 拜耳知识产权有限责任公司 | 用于治疗过增生症状和与血管生成有关疾病的缺氧诱导因子(hif)抑制剂 |
CN101868251B (zh) | 2007-08-06 | 2012-10-10 | 千寿制药株式会社 | 含有HIF-1α和HIF-2α表达抑制物质的药物 |
TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
KR20100045480A (ko) | 2007-08-10 | 2010-05-03 | 크리스탈지노믹스(주) | 피리딘 유도체 및 이들의 사용방법 |
WO2009035534A2 (en) | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
WO2009043093A1 (en) | 2007-10-04 | 2009-04-09 | Newsouth Innovations Pty Limited | Hif inhibition |
WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
WO2009067790A1 (en) | 2007-11-26 | 2009-06-04 | Uti Limited Partnership | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION |
CN101983384A (zh) | 2007-11-30 | 2011-03-02 | 葛兰素史密斯克莱有限责任公司 | 脯氨酰羟化酶抑制剂 |
JP2011505367A (ja) | 2007-11-30 | 2011-02-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
JP2011507894A (ja) | 2007-12-19 | 2011-03-10 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
WO2009086592A1 (en) | 2008-01-04 | 2009-07-16 | Garvan Institute Of Medical Research | Method of increasing metabolism |
EP2252619B1 (en) | 2008-01-11 | 2013-10-09 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity |
EA018068B1 (ru) * | 2008-03-03 | 2013-05-30 | Айрм Ллк | Соединения и композиции в качестве модуляторов активности tlr |
US20090228298A1 (en) * | 2008-03-04 | 2009-09-10 | The General Electric Company | System and method of morphology feature analysis of physiological data |
MX2010010241A (es) * | 2008-03-20 | 2010-12-06 | Forest Lab Holdings Ltd | Derivados de piperidina novedosos como inhibidores de estearoil-coa desaturasa. |
AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
BRPI0916233A2 (pt) | 2008-07-23 | 2018-03-13 | F.Hoffman-La Roche Ag | compostos heterocíclicos antivirais |
BRPI0913485A2 (pt) | 2008-09-15 | 2016-06-07 | Kasina Laila Innova Pharmaceuticals Private Ltd | medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres. |
CN102272117B (zh) | 2008-11-14 | 2015-06-17 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
CN102365281B (zh) | 2009-03-31 | 2014-11-12 | 橘生药品工业株式会社 | 中氮茚衍生物及其医药用途 |
WO2011057115A1 (en) | 2009-11-06 | 2011-05-12 | Akebia Therapeutics Inc. | Prolyl hydroxylase inhibitors |
NO2686520T3 (it) * | 2011-06-06 | 2018-03-17 | ||
US8865748B2 (en) * | 2011-06-06 | 2014-10-21 | Akebia Therapeutics Inc. | Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
US20130022974A1 (en) | 2011-06-17 | 2013-01-24 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
CN104024227B (zh) | 2011-07-22 | 2015-12-02 | 北京贝美拓新药研发有限公司 | 抑制脯氨酸羟化酶活性的化合物的晶型及其应用 |
US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
RU2019134558A (ru) | 2013-06-13 | 2020-02-20 | Экебиа Терапьютикс, Инк. | Композиции и способы лечения анемии |
MX2016002014A (es) | 2013-08-16 | 2016-07-21 | Ohio State Innovation Foundation | Composiciones y metodos para modular la metilacion de dna. |
KR102381295B1 (ko) | 2013-11-15 | 2022-03-31 | 아케비아 테라퓨틱스 인코포레이티드 | {[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노}아세트산의 고체형, 이의 조성물 및 용도 |
MX2016009331A (es) | 2014-01-23 | 2016-10-26 | Akebia Therapeutics Inc | Composiciones y metodos para tratar enfermedades oculares. |
TW201632504A (zh) | 2015-01-23 | 2016-09-16 | 阿克比治療有限公司 | 2-(5-(3-氟苯基)-3-羥吡啶醯胺基)乙酸之固體形式、其組合物及其用途 |
WO2016153996A1 (en) | 2015-03-20 | 2016-09-29 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
BR112017021097B1 (pt) | 2015-04-01 | 2024-01-02 | Akebia Therapeutics, Inc | Formulação de dosagem oral e seu uso |
KR20210006967A (ko) | 2018-05-09 | 2021-01-19 | 아케비아 테라퓨틱스 인코포레이티드 | 2-[[5-(3-클로로페닐)-3-하이드록시피리딘-2-카르보닐]아미노]아세트산을 제조하는 방법 |
-
2012
- 2012-03-05 NO NO12759983A patent/NO2686520T3/no unknown
- 2012-06-05 EP EP21206374.7A patent/EP4026829A1/en active Pending
- 2012-06-05 WO PCT/US2012/040833 patent/WO2012170377A1/en active Application Filing
- 2012-06-05 LT LTEP19214405.3T patent/LT3683209T/lt unknown
- 2012-06-05 HU HUE19214405A patent/HUE057571T2/hu unknown
- 2012-06-05 DK DK15189822.8T patent/DK3000808T3/da active
- 2012-06-05 JP JP2014514536A patent/JP6290781B2/ja active Active
- 2012-06-05 ES ES17191362T patent/ES2771232T3/es active Active
- 2012-06-05 MX MX2015016579A patent/MX347709B/es unknown
- 2012-06-05 CN CN201610967348.7A patent/CN106518759B/zh active Active
- 2012-06-05 SI SI201230432T patent/SI2718265T1/sl unknown
- 2012-06-05 RS RS20200130A patent/RS59902B1/sr unknown
- 2012-06-05 DK DK17191362.7T patent/DK3290404T3/da active
- 2012-06-05 PL PL17191362T patent/PL3290404T3/pl unknown
- 2012-06-05 RU RU2013158640/04A patent/RU2602083C2/ru active
- 2012-06-05 HU HUE17191362A patent/HUE048044T2/hu unknown
- 2012-06-05 PL PL19214405T patent/PL3683209T3/pl unknown
- 2012-06-05 KR KR1020147000297A patent/KR102000485B1/ko active IP Right Grant
- 2012-06-05 US US13/488,554 patent/US9145366B2/en active Active
- 2012-06-05 AU AU2012268426A patent/AU2012268426B2/en active Active
- 2012-06-05 RS RS20160013A patent/RS54517B1/en unknown
- 2012-06-05 KR KR1020197037296A patent/KR102171315B1/ko active IP Right Grant
- 2012-06-05 RS RS20171181A patent/RS56580B1/sr unknown
- 2012-06-05 PT PT171913627T patent/PT3290404T/pt unknown
- 2012-06-05 DK DK19214405.3T patent/DK3683209T3/da active
- 2012-06-05 PT PT127963742T patent/PT2718265E/pt unknown
- 2012-06-05 CA CA3135440A patent/CA3135440A1/en active Pending
- 2012-06-05 RU RU2016139352A patent/RU2764667C2/ru active
- 2012-06-05 KR KR1020197007630A patent/KR102059366B1/ko active IP Right Grant
- 2012-06-05 SI SI201231114T patent/SI3000808T1/en unknown
- 2012-06-05 LT LTEP15189822.8T patent/LT3000808T/lt unknown
- 2012-06-05 HU HUE12796374A patent/HUE026096T2/en unknown
- 2012-06-05 PL PL15189822T patent/PL3000808T3/pl unknown
- 2012-06-05 MX MX2013014228A patent/MX337216B/es active IP Right Grant
- 2012-06-05 EP EP19214405.3A patent/EP3683209B1/en active Active
- 2012-06-05 KR KR1020207029586A patent/KR102293016B1/ko active IP Right Grant
- 2012-06-05 HR HRP20211916TT patent/HRP20211916T1/hr unknown
- 2012-06-05 ES ES15189822.8T patent/ES2647602T3/es active Active
- 2012-06-05 PT PT151898228T patent/PT3000808T/pt unknown
- 2012-06-05 CA CA2838194A patent/CA2838194C/en active Active
- 2012-06-05 EP EP12796374.2A patent/EP2718265B1/en active Active
- 2012-06-05 KR KR1020197007633A patent/KR102032864B1/ko active IP Right Grant
- 2012-06-05 DK DK12796374.2T patent/DK2718265T3/en active
- 2012-06-05 PT PT192144053T patent/PT3683209T/pt unknown
- 2012-06-05 ES ES12796374.2T patent/ES2559850T3/es active Active
- 2012-06-05 HU HUE15189822A patent/HUE034975T2/en unknown
- 2012-06-05 SI SI201231969T patent/SI3683209T1/sl unknown
- 2012-06-05 EP EP15189822.8A patent/EP3000808B1/en active Active
- 2012-06-05 EP EP17191362.7A patent/EP3290404B1/en active Active
- 2012-06-05 ES ES19214405T patent/ES2900572T3/es active Active
- 2012-06-05 SI SI201231729T patent/SI3290404T1/sl unknown
- 2012-06-05 PL PL12796374T patent/PL2718265T3/pl unknown
- 2012-06-05 LT LTEP17191362.7T patent/LT3290404T/lt unknown
-
2013
- 2013-12-03 IL IL229775A patent/IL229775A/en active IP Right Grant
-
2014
- 2014-10-10 HK HK14110125.1A patent/HK1196616A1/zh unknown
-
2015
- 2015-08-24 US US14/833,222 patent/US9776969B2/en active Active
- 2015-12-23 HR HRP20151416T patent/HRP20151416T1/hr unknown
-
2016
- 2016-01-14 CY CY20161100037T patent/CY1117177T1/el unknown
- 2016-01-15 SM SM201600013T patent/SMT201600013B/it unknown
- 2016-04-07 HK HK16104004.8A patent/HK1216173A1/zh unknown
-
2017
- 2017-04-12 AU AU2017202414A patent/AU2017202414B2/en active Active
- 2017-08-31 US US15/692,255 patent/US10246416B2/en active Active
- 2017-11-13 HR HRP20171740TT patent/HRP20171740T1/hr unknown
- 2017-11-15 CY CY20171101202T patent/CY1119605T1/el unknown
-
2018
- 2018-02-08 JP JP2018020595A patent/JP6510094B2/ja active Active
- 2018-09-05 HK HK18111429.8A patent/HK1252109A1/zh unknown
- 2018-10-15 AU AU2018250355A patent/AU2018250355B2/en active Active
-
2019
- 2019-03-13 US US16/352,705 patent/US10738010B2/en active Active
- 2019-04-03 JP JP2019070979A patent/JP6816195B2/ja active Active
-
2020
- 2020-02-03 CY CY20201100087T patent/CY1122639T1/el unknown
- 2020-02-06 HR HRP20200197TT patent/HRP20200197T1/hr unknown
- 2020-07-06 US US16/921,273 patent/US11267785B2/en active Active
- 2020-07-07 AU AU2020204528A patent/AU2020204528B2/en active Active
- 2020-12-23 JP JP2020213442A patent/JP7039682B2/ja active Active
-
2021
- 2021-12-08 CY CY20211101079T patent/CY1124874T1/el unknown
-
2022
- 2022-01-31 US US17/589,118 patent/US20230002323A1/en active Pending
- 2022-03-09 JP JP2022035813A patent/JP7284309B2/ja active Active
-
2023
- 2023-05-18 JP JP2023081959A patent/JP2023103414A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT201600013B (it) | Procedimento per la preparazione di acidi, esteri e ammidi [(3-idrossipiridin-2-carbonil) ammino]alcanoici | |
HRP20181696T1 (hr) | Postupak za pripremu dipeptidnih derivata lizin-glutaminske kiseline | |
SMT201600464B (it) | Procedimento per la preparazione di esterolo | |
HK1200851A1 (en) | Etanercept formulations stabilized with amino acids | |
ZA201502991B (en) | Disubstituted amino acids and methods of preparation and use thereof | |
EP2771033A4 (en) | PROTEIN FORMULATIONS CONTAINING AMINO ACIDS | |
EP2649178B8 (en) | Mgmt-based method for obtaining high yield of recombinant protein expression | |
EP2804488A4 (en) | METHOD OF INSTANCING AMINO ACIDS | |
SMT201500327B (it) | Procedimento per la preparazione di esteri di acido (5-fluoro-2-metil-3-chinolin-2-ilmetil-indol-1-il)-acetico | |
IL225606A0 (en) | A method for preparing an inactive supplement suitable for pharmaceutical use | |
IT1403282B1 (it) | Procedimento per la preparazione di linagliptin | |
PT2757878E (pt) | Método para a preparação e aperfeiçoamento de ferraduras | |
PL2726486T3 (pl) | Nowe estry n-acylowanych pochodnych aminokwasów i izosorbidu, sposób ich wytwarzania i ich zastosowanie w kosmetyku i jako leku | |
NO20110238A1 (no) | Fremgangsmåte for fremstilling av aminoalkoholer | |
EP2726652A4 (en) | PROCESS FOR PROTEIN DISPLAY | |
ITMI20121077A1 (it) | Macchina e metodo per la preparazione di bevande | |
IL231645A (en) | Process for making isoxazolyl - methoxy - nicotinic acids | |
EP2736912A4 (en) | METHODS FOR THE ISOLATION OF 4-CHLORO-2-FLUORO-PHENYLBORONIC ACIDS SUBSTITUTED IN POSITION 3 | |
FI20105629A0 (fi) | Menetelmä lipidiaktivoituvien entsyymien peptidi-inhibiittoreiden valmistamiseksi ja menetelmällä valmistettuja peptidejä | |
PL2791201T3 (pl) | Sposób wytwarzania określonych funkcjonalnych oligomerów kwasu mlekowego | |
LT2673282T (lt) | Drono rūgščių naujas gavimo būdas | |
SM201000062A (it) | Processo per la preparazione di gabapentin | |
HUE054747T2 (hu) | Eljárás közvetlenül tablettázható delta-mannit elõállítására | |
PL399050A1 (pl) | Estry difenylowe pochodne kwasów 1-izotiocyjano-metanofosfonowych, sposób ich wytwarzania i zastosowanie | |
TH1201000802B (th) | วิธีการสำหรับการผลิตกรด แอล-อะมิโน |